Related Experiment Video
Updated: Jan 30, 2026
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Characterization of drug binding within the HCN1 channel pore
Jérémie Tanguay1, Karen M Callahan2, Nazzareno D'Avanzo3
1Department of Physics, Université de Montréal, Montréal, Canada.
Insights
Researchers used computational docking to study how drugs bind to HCN channels. They identified a hydrophobic groove that explains low drug affinity, guiding the development of more effective treatments for heart and neurological conditions.
Area of Science:
- Molecular Biology
- Pharmacology
- Neuroscience
Background:
- Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are crucial for cardiac pacemaker activity and neuronal functions like setting membrane potentials and action potential thresholds.
- HCN channel blockers are used to treat angina and show promise for epilepsy and neuropathic pain, but current drugs have low affinity and specificity.
- Existing HCN channel inhibitors include clonidine, lidocaine, and ivabradine, yet their binding mechanisms within the channel pore remain unclear.
Purpose of the Study:
- To computationally investigate the binding sites and modes of known HCN channel inhibitors.
- To elucidate the molecular basis for the low affinity and specificity of current HCN channel blocking drugs.
- To identify structural features that can guide the design of novel, high-affinity HCN channel modulators.
Main Methods:
- Computational docking experiments were performed using the atomic structure of human HCN1 channels.
- A homology model of the open pore from a related CNG channel was utilized for docking simulations.
- Analysis focused on assessing inhibitor binding sites and orientation within the HCN channel pore.
Main Results:
- A hydrophobic groove was identified within the pore cavity of HCN channels.
- This groove appears to conformationally restrict the location and orientation of bound inhibitors in the inner vestibule.
- The findings provide a molecular explanation for the observed low-affinity binding of current HCN channel blockers.
Conclusions:
- The identified hydrophobic groove is a key structural determinant influencing drug binding to HCN channels.
- Understanding this binding pocket is essential for rational drug design.
- These results pave the way for developing novel HCN channel inhibitors with improved affinity and specificity for therapeutic applications.
Abstract:
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels mediate rhythmic electrical activity of cardiac pacemaker cells, and in neurons play important roles in setting resting membrane potentials, dendritic integration, neuronal pacemaking, and establishing action potential threshold. Block of HCN channels slows the heart rate and is currently used to treat angina. However, HCN block also provides a promising approach to the treatment of neuronal disorders including epilepsy and neuropathic pain. While several molecules that block HCN channels have been identified, including clonidine and its derivative alinidine, lidocaine, mepivacaine, bupivacaine, ZD7288, ivabradine, zatebradine, and cilobradine, their low affinity and lack of specificity prevents wide-spread use. Different studies suggest that the binding sites of these inhibitors are located in the inner vestibule of HCN channels, but the molecular details of their binding remain unknown. We used computational docking experiments to assess the binding sites and mode of binding of these inhibitors against the recently solved atomic structure of human HCN1 channels, and a homology model of the open pore derived from a closely related CNG channel. We identify a possible hydrophobic groove in the pore cavity that plays an important role in conformationally restricting the location and orientation of drugs bound to the inner vestibule. Our results also help explain the molecular basis of the low-affinity binding of these inhibitors, paving the way for the development of higher affinity molecules.
More Related Videos
Related Concept Videos
01:19Ion Channels
Ion channels are specialized integral membrane proteins on the plasma membrane that allow...
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
01:24Tissue-Drug Binding: Localization of Drugs and its Significance
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
01:21Drug Distribution: Tissue Binding
For...
01:30Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...